Sirota Valentina B, Zhumakayeva Sabina Sakenovna, Kabildina Nailya Amirbekovna, Dorogan Daria Dmitrievna, Bilyalova Zarina, Adekenov Sergazy M
NCJSC "Karaganda Medicinal University", Karaganda, Republic of Kazakhstan.
JSC "International Research and Production Holding "Phytochemistry", Republic of Kazakhstan.
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4123-4128. doi: 10.31557/APJCP.2024.25.12.4123.
Within the framework of multicenter clinical studies of the original anticancer drug "Arglabin" in the complex therapy of breast cancer (BC) in an increased dose on the basis of the Regional Oncological Dispensary, Karaganda, 80 patients BC were examined and treated: 40 patients in the control group and 40 in the study group. The index of grade I anemia was higher in patients of the control group: in (15.6±6.42)% of patients with polychemotherapy (PCT) AC and in (6.9±4.7)% of patients with PCT according to the scheme AC+Arglabin (p<0.05). The inclusion of Arglabin to the AC regimen increases the rate of absence of toxicity to blood leukocytosis by 25.2% (69.0±8.6%) compared with the group of patients receiving APCT according to the AC regimen (43.8±8.8%); decrease in grade I leukopenia by 2.7 times (from 28.13±7.95% to 10.3±5.7%, p≤0.05); 2-fold decrease in grade 2 leukopenia (from 28.1±7.95% to 13.8±6.4%). The inclusion of Arglabin to the AC regimen in APCT in BC patients increases the rate of absence of toxicity to blood granulocytosis by 14.8% (67.9±8.8%) compared to the group of patients who received APCT according to the AC regimen (53.1±8.8%); a decrease in grade 2 granulocytopenia by 3.9 times (from 28.1±7.95% to 7.14±4.9%, p≤0.05). The inclusion of Arglabin to the adjuvant chemotherapy regimen eliminates the toxic effect of chemotherapy on erythrocytosis, leukocytosis and granulocytosis. No effect of arglabin on blood platelets indicators in breast cancer patients was revealed.
在卡拉干达地区肿瘤防治所开展的多中心临床研究框架内，对原研抗癌药物“阿格拉宾”以增加剂量用于乳腺癌（BC）综合治疗进行了研究，共检查和治疗了80例BC患者：对照组40例患者，研究组40例患者。对照组患者中I级贫血指数更高：接受多药联合化疗（PCT）AC方案的患者中为（15.6±6.42）%，接受AC + 阿格拉宾方案PCT的患者中为（6.9±4.7）%（p<0.05）。与接受AC方案PCT的患者组（43.8±8.8%）相比，在AC方案中加入阿格拉宾可使对血液白细胞增多无毒性反应的发生率提高25.2%（69.0±8.6%）；I级白细胞减少症减少2.7倍（从28.13±7.95%降至10.3±5.7%，p≤0.05）；2级白细胞减少症减少2倍（从28.1±7.95%降至13.8±6.4%）。在BC患者的辅助化疗（APCT）中，在AC方案中加入阿格拉宾可使对血液粒细胞增多无毒性反应的发生率比接受AC方案APCT的患者组提高14.8%（67.9±8.8%）；2级粒细胞减少症减少3.9倍（从28.1±7.95%降至7.14±4.9%，p≤0.05）。在辅助化疗方案中加入阿格拉宾可消除化疗对红细胞增多、白细胞增多和粒细胞增多的毒性作用。未发现阿格拉宾对乳腺癌患者血小板指标有影响。
